Similar to HER3, bladder cancer tumors expressing specific HER4 isoform demonstrate improved patient survival in the absence of ER-α (Junttila et al., 2003; Memon et al., 2004), further research indicate that ER-α inhibition may be a useful treatment for bladder cancer patients with overexpression of both ER-α and HER4 (Munk et al., 2013). The gene discussed is ERBB3; the disease is urinary bladder carcinoma.